[go: up one dir, main page]

WO2010096886A3 - Composition de gel liposomique contenant de l'hydrocortisone, ses métabolites, ses précurseurs ou un mélange desdits, et utilisation associée - Google Patents

Composition de gel liposomique contenant de l'hydrocortisone, ses métabolites, ses précurseurs ou un mélange desdits, et utilisation associée Download PDF

Info

Publication number
WO2010096886A3
WO2010096886A3 PCT/BE2010/000015 BE2010000015W WO2010096886A3 WO 2010096886 A3 WO2010096886 A3 WO 2010096886A3 BE 2010000015 W BE2010000015 W BE 2010000015W WO 2010096886 A3 WO2010096886 A3 WO 2010096886A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolites
precursors
mixtures
composition
hydrocortisone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BE2010/000015
Other languages
English (en)
Other versions
WO2010096886A2 (fr
Inventor
Gina Van Bogaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/203,059 priority Critical patent/US20110308985A1/en
Priority to EP10716254A priority patent/EP2400952A2/fr
Publication of WO2010096886A2 publication Critical patent/WO2010096886A2/fr
Publication of WO2010096886A3 publication Critical patent/WO2010096886A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un gel liposomique contenant, outre les liposomes et une phase continue, au moins un agent épaississant, au moins un matériau biologiquement actif et, de manière optionnelle, au moins un additif ; le matériau biologiquement actif est encapsulé dans les liposomes, ledit matériau étant constitué d'hydrocortisone, de ses métabolites, de ses précurseurs ou d'un mélange desdits et étant appliqué sur la peau à des fins thérapeutiques, et ledit matériau étant caractérisé en ce que le rapport de poids phosphatidylcholine/hydrocortisone atteint au moins 2/1 et/ou en ce que le rapport de poids phosphatidylcholine/hydrogel de carbomère atteint au moins 20/1.
PCT/BE2010/000015 2009-02-26 2010-02-26 Composition de gel liposomique contenant de l'hydrocortisone, ses métabolites, ses précurseurs ou un mélange desdits, et utilisation associée Ceased WO2010096886A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/203,059 US20110308985A1 (en) 2009-02-26 2010-02-26 Composition of a liposomal gel containing hydrocortisone, its metabolites, precursors or mixtures thereof and the use thereof
EP10716254A EP2400952A2 (fr) 2009-02-26 2010-02-26 Composition de gel liposomique contenant de l'hydrocortisone, ses métabolites, ses précurseurs ou un mélange desdits, et utilisation associée

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2009/0120A BE1018506A3 (nl) 2009-02-26 2009-02-26 Samenstelling van een hydrocortisone, zijn derivaten, metabolieten, prodrugs of mengsels daarvan houdende liposomale gel en het gebruik ervan.
BE2009/0120 2009-02-26

Publications (2)

Publication Number Publication Date
WO2010096886A2 WO2010096886A2 (fr) 2010-09-02
WO2010096886A3 true WO2010096886A3 (fr) 2011-06-16

Family

ID=41129255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2010/000015 Ceased WO2010096886A2 (fr) 2009-02-26 2010-02-26 Composition de gel liposomique contenant de l'hydrocortisone, ses métabolites, ses précurseurs ou un mélange desdits, et utilisation associée

Country Status (3)

Country Link
EP (1) EP2400952A2 (fr)
BE (1) BE1018506A3 (fr)
WO (1) WO2010096886A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1030538B1 (nl) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan
CN116602921A (zh) * 2023-04-20 2023-08-18 江苏艾迪纳米生物医药有限公司 一种磷酸氯喹阳离子柔性脂质体凝胶及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190936A (en) * 1989-06-15 1993-03-02 L'oreal Process for improving the therapeutic efficacy of fat-soluble corticosteroids and composition for carrying out this process
DE19940227A1 (de) * 1999-08-25 2001-03-08 Merckle Gmbh Phospholipidgel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190936A (en) * 1989-06-15 1993-03-02 L'oreal Process for improving the therapeutic efficacy of fat-soluble corticosteroids and composition for carrying out this process
DE19940227A1 (de) * 1999-08-25 2001-03-08 Merckle Gmbh Phospholipidgel

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "MedlinePlus Medical Encyclopedia: Cortisol - urine", 8 October 2008 (2008-10-08), pages 1 - 3, XP002629132, Retrieved from the Internet <URL:http://replay.waybackmachine.org/20081008094639/http://www.nlm.nih.gov/medlineplus/ency/article/003703.htm> [retrieved on 20110318] *
K. PARFITT (ED.): "Martindale. The comple drug reference. 32nd edition.", 1999, PHARMACEUTICAL PRESS, LONDON, XP002549295 *
KIM M-K ET AL: "Targeted and sustained delivery of hydrocortisone to normal and stratum corneum-removed skin without enhanced skin absorption using a liposome gel", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 46, no. 3, 2 June 1997 (1997-06-02), pages 243 - 251, XP004092170, ISSN: 0168-3659 *
NAUNTON MARK ET AL: "Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women.", MENOPAUSE (NEW YORK, N.Y.) 2006 MAY-JUN, vol. 13, no. 3, May 2006 (2006-05-01), pages 517 - 527, XP002549294, ISSN: 1072-3714 *

Also Published As

Publication number Publication date
WO2010096886A2 (fr) 2010-09-02
EP2400952A2 (fr) 2012-01-04
BE1018506A3 (nl) 2011-02-01

Similar Documents

Publication Publication Date Title
MY151268A (en) Novel thermosensitive liposomes containing therapeutic agents
EP4403172A3 (fr) Polyvinylpyrrolidone pour la stabilisation d&#39;une dispersion solide de la forme non cristalline de rotigotine
PL2210588T3 (pl) Kompozycje pianotwórcze do leczenia skóry ludzkiej zasadniczo niezawierające aktywnych składników farmaceutycznych
WO2010041141A3 (fr) Support expansible à base d’huile et préparations
WO2009090495A3 (fr) Vecteurs moussants siliconés à base d&#39;huile et de liquide, et formulations
WO2010097480A3 (fr) Composés de menthyl carbamate utilisés en tant que principes actifs d&#39;éclaircissement de la peau et/ou des cheveux
MY152985A (en) Cosmetic or pharmaceutical composition, to be applied topically
WO2005055983A3 (fr) Procede de preparation de cocristaux a phase mixte avec des agents actifs
NZ703808A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
UA86063C2 (ru) Липосомы для снабжения лекарств
WO2010149798A4 (fr) Utilisation de polyols pour augmenter l&#39;effet de refroidissement d&#39;une substance refroidissante et mélanges refroidissants ayant un plus grand effet de refroidissement
CL2009000697A1 (es) Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras.
PL1791532T3 (pl) Kompozycja w mikropeletkach o kontrolowanym uwalnianiu substancji fizjologicznie czynnych, sposób jej wytwarzania i jej zastosowanie w dziedzinie zootechniki
WO2009026427A3 (fr) Compositions à base de liposomes pour une administration in vivo de composés d&#39;acide boronique
WO2012066488A3 (fr) Dérivés à ponts ester de spiro [2.4] heptane
WO2008151040A3 (fr) Produit médical enrobé d&#39;analgésique
BRPI0414014A (pt) métodos para distribuição intradérmica de agentes terapêuticos
PH12014501866A1 (en) Thermosensitive nanoparticle formulations and method of making the same
WO2005094783A3 (fr) Liposomes amphoteres a stabilite serique
WO2012070804A3 (fr) Composition cosmétique contenant un acide oléanolique
WO2006051549A3 (fr) Therapie combinee
MX2009013708A (es) Uso de derivados de acido tetramico para combatir vectores transmisores de virus.
CL2008000495A1 (es) Compuestos derivados de tetrahidro-pirazolo[4,3-c]piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alergias, inflamacion, dolor, cancer, entreotras.
WO2010096886A3 (fr) Composition de gel liposomique contenant de l&#39;hydrocortisone, ses métabolites, ses précurseurs ou un mélange desdits, et utilisation associée
WO2013000651A8 (fr) Dérivés d&#39;arylalkylaminocarboxamides fluorés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10716254

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13203059

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010716254

Country of ref document: EP